I consider myself a 50/50 technical/fundamental trader and investor. I have carved a niche in analyzing small cap biotechnology companies and analyzing trial data, design and company structure. I mainly trade catalyst-driven stocks with good cash positions and promising therapies. Overall, my specialty is trial data. Over the past 6 years of research and investing, I have learned of the many ways to make money trading these extremely volatile and speculative biotech plays, particularly by making the best assumptions and educated guesses possible on trial data and company structure and management. I play the FDA calendar and pick the best companies possible for run-ups to data. I also do research for Stockmatusow.com, and collaborate with Scott Matusow and Kyle Dennis on articles and trade calls.